nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—Thalidomide—FGFR2—cleft lip	0.299	1	CrCbGaD
Pomalidomide—TNF—Allograft Rejection—BHMT2—cleft lip	0.0618	0.0882	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—MTHFS—cleft lip	0.0541	0.0772	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—BCL3—cleft lip	0.0489	0.0698	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—TFAP2A—cleft lip	0.035	0.0499	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—NOG—cleft lip	0.0334	0.0476	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—BHMT2—cleft lip	0.0271	0.0387	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—TCN2—cleft lip	0.0246	0.0351	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—SLC19A1—cleft lip	0.0242	0.0345	CbGpPWpGaD
Pomalidomide—CYP1A2—Methylation—MTR—cleft lip	0.022	0.0314	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IRF6—cleft lip	0.0205	0.0292	CbGpPWpGaD
Pomalidomide—ABCB1—ABC-family proteins mediated transport—ABCA4—cleft lip	0.0188	0.0269	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—MTR—cleft lip	0.0171	0.0243	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—BMP4—cleft lip	0.0163	0.0233	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—SUMO1—cleft lip	0.0162	0.0232	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP63—cleft lip	0.0142	0.0203	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—MTR—cleft lip	0.0139	0.0198	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—cleft lip	0.012	0.0171	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB3—cleft lip	0.0118	0.0168	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—MTR—cleft lip	0.011	0.0157	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TCN2—cleft lip	0.00993	0.0142	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—MTHFR—cleft lip	0.00914	0.013	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—FGFR2—cleft lip	0.00894	0.0128	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NODAL—cleft lip	0.00856	0.0122	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—BMP4—cleft lip	0.00807	0.0115	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—MTHFR—cleft lip	0.00743	0.0106	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTR—cleft lip	0.00688	0.00982	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MTR—cleft lip	0.00682	0.00973	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—FGF2—cleft lip	0.00656	0.00937	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—cleft lip	0.00647	0.00924	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—FGFR2—cleft lip	0.00637	0.00909	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EPHA3—cleft lip	0.00621	0.00886	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—FGF2—cleft lip	0.00608	0.00868	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—MTHFR—cleft lip	0.00591	0.00843	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NODAL—cleft lip	0.00529	0.00755	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—cleft lip	0.00459	0.00655	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—cleft lip	0.00443	0.00633	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—FGF2—cleft lip	0.00433	0.00619	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NODAL—cleft lip	0.004	0.00571	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—MTR—cleft lip	0.00386	0.00551	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NODAL—cleft lip	0.00375	0.00536	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—cleft lip	0.00369	0.00526	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—cleft lip	0.00365	0.00521	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.00364	0.00519	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FGFR1—cleft lip	0.00341	0.00486	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.00308	0.00439	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—cleft lip	0.00284	0.00405	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—cleft lip	0.00283	0.00404	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—MTR—cleft lip	0.00226	0.00322	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.00225	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.00225	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—cleft lip	0.00216	0.00308	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ABCA4—cleft lip	0.00197	0.00281	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—FGF10—cleft lip	0.00192	0.00274	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—cleft lip	0.00191	0.00273	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.0019	0.00271	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—cleft lip	0.00175	0.0025	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—MTR—cleft lip	0.00174	0.00249	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT9B—cleft lip	0.00174	0.00248	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—cleft lip	0.00163	0.00232	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—cleft lip	0.00161	0.00229	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—cleft lip	0.00159	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ABCA4—cleft lip	0.00155	0.00221	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.00147	0.0021	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—FGFR1—cleft lip	0.00144	0.00205	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC19A1—cleft lip	0.00142	0.00202	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.00139	0.00198	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT3—cleft lip	0.00138	0.00197	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—cleft lip	0.00135	0.00192	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—cleft lip	0.00134	0.00191	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC19A1—cleft lip	0.00119	0.0017	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TCN2—cleft lip	0.00118	0.00168	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—FGF2—cleft lip	0.00105	0.0015	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.000985	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TCN2—cleft lip	0.000985	0.0014	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SPRY2—cleft lip	0.000914	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF7—cleft lip	0.000914	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000908	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF8—cleft lip	0.000844	0.0012	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC19A1—cleft lip	0.000842	0.0012	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTR—cleft lip	0.000815	0.00116	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TCN2—cleft lip	0.000698	0.000996	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF3—cleft lip	0.000687	0.00098	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTR—cleft lip	0.000682	0.000974	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC19A1—cleft lip	0.000672	0.000959	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF9—cleft lip	0.00067	0.000956	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.000644	0.000919	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF10—cleft lip	0.000565	0.000806	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TCN2—cleft lip	0.000557	0.000795	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC19A1—cleft lip	0.000519	0.00074	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTR—cleft lip	0.000484	0.00069	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR2—cleft lip	0.000453	0.000647	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—cleft lip	0.000436	0.000623	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TCN2—cleft lip	0.00043	0.000614	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR1—cleft lip	0.000422	0.000603	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—cleft lip	0.000418	0.000597	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR3—cleft lip	0.000399	0.00057	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTR—cleft lip	0.000386	0.000551	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—cleft lip	0.000365	0.000521	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF2—cleft lip	0.000309	0.00044	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—cleft lip	0.000304	0.000434	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTR—cleft lip	0.000298	0.000425	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—cleft lip	0.000297	0.000423	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—cleft lip	0.000259	0.00037	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—cleft lip	0.000255	0.000364	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—cleft lip	0.000237	0.000338	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—cleft lip	0.000207	0.000295	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—cleft lip	0.000202	0.000288	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—cleft lip	0.000183	0.000261	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—cleft lip	0.000181	0.000258	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—cleft lip	0.00016	0.000228	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—cleft lip	0.000144	0.000206	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—cleft lip	0.000111	0.000159	CbGpPWpGaD
